Literature DB >> 13044990

Lichen myxedematosus; differentiation from cutaneous myxedemas or mucoid states.

H MONTGOMERY, L J UNDERWOOD.   

Abstract

Entities:  

Keywords:  LICHEN; MYXEDEMA

Mesh:

Substances:

Year:  1953        PMID: 13044990     DOI: 10.1038/jid.1953.25

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  23 in total

1.  [Etiology & pathogenesis of circumscribed pretibial symmetric myxedema].

Authors:  P WODNIANSKY
Journal:  Arch Klin Exp Dermatol       Date:  1957

2.  [Not Available].

Authors:  J KONRAD; A WINKLER
Journal:  Arch Klin Exp Dermatol       Date:  1956

3.  [Not Available].

Authors:  J TAPPEINER
Journal:  Arch Klin Exp Dermatol       Date:  1955

4.  [Scleromyxedema. A chronic progressive systemic disease].

Authors:  A Kreuter; M Stücker; A G A Kolios; P Altmeyer; K Möllenhoff
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

5.  Generalized follicular mucinosis with myxaedema.

Authors:  K Grice; D Doniach; E Wilson-Jones; S C Gold
Journal:  Proc R Soc Med       Date:  1968-07

6.  [Myxodermia tuberosa circumscripta euthyreotica].

Authors:  P Wodniansky
Journal:  Arch Klin Exp Dermatol       Date:  1966

7.  Synthesis of glycosaminoglycans and collagen in skin fibroblasts cultured from a patient with lichen myxedematosus.

Authors:  H Turakainen; M Välimäki; R Penttinen
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

8.  Papular mucinosis with IgG(K) M component.

Authors:  F W Danby; C W Danby; W Pruzanski
Journal:  Can Med Assoc J       Date:  1976-05-22       Impact factor: 8.262

9.  Plaque-Like Sclerodermiform Localized Mucinosis Rapidly Responsive to Topical Tacrolimus.

Authors:  R Schmaltz; T Vogt; C S L Müller
Journal:  Case Rep Dermatol       Date:  2010-09-01

10.  Papular mucinosis, destructive arthropathy, median neuropathy, and sicca complex.

Authors:  R A Frayha
Journal:  Clin Rheumatol       Date:  1983-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.